Supplementary Table 3.

General characteristics of the included studies for favipiravir

Name of first author, Year	Study site	Population	Research Design	Intervention	Comparator	Primary Outcome	Outcome measurement	Sample size in intervention	Sample size in comparator	Outcome in intervention	Outocme in control
Chen C et al.,2020	China	Adult patients with COVID-19, moderate, severe or critical	Open-label, randomized, controlled trial	Favipiravir	Umifenovir (Arbidol)	Clinical recovery rate of Day 7	Clinical recovery was defined as continuous recovery of body temp., respiratory rate, oxygen saturation and cough relief	116	120	61.21%	51.67%
Cai Q et al.,2020	China	Adults with moderate COVID-19	Open-label, non- randomized controlled study	Favipiravir + INF-α 1b	LPV/RTV + INF-α 1b	a. Time of viral clearance b. Improvement rate of chest computed tomography (CT) scans on Day 14 after treatment	a. Median time in days of viral clearance b. Chest CT score*	35	45	a. 4 d (IQR: 2.5-9) b. 91.4%	a. 11 d (IQR: 8-13) b. 62.2%
lou Y et al.,2020	China	COVID-19 patients	Open-label, randomized, controlled trial	a. Favipiravir b. Baloxavir	Existing antiviral treatment	a. Time to Viral negativity b. Time to clinical improvement	a.Viral negative at Day 14 b. Time to clinical improvement - median no. of days (IQR)	a. 9 b. 10	10	a. 70%, 77% b. 14 (6-49), 14 (6-38)	1. 100% 2.15 (6-24)
Doi Y et al., 2020	Japan	Patients of age >10 years with mild, moderate and severe COVID-19	Observational study	Favipiravir	None	Clinical improvement	a. Clinical improvement at 7 and 14 days b. Positive clinical outcome 1 month into hospitalization	2158+	None	a. 67%, 83% b. 57%	-

LPV/RTV - Lopinavir-ritonavir, INF- Interferon , +Clinical status at day 7, clinical status at day 14, clinical outcome at one month were available for 1,713, 1,282 and 1,918 cases